Skip to main content
Premium Trial:

Request an Annual Quote

Tempus Lens Platform

Tempus has launched Lens, a cloud-based data and analytics platform designed to provide researchers at biotech and pharma companies with short-term, on-demand access to more than 35 petabytes of deidentified clinical and molecular datasets, as well as artificial intelligence analytical tools to accelerate drug discovery and development.

The Lens platform enables users to access, analyze, and build upon Tempus' library of clinical and molecular data, including tumor/normal matched DNA, RNA, and H&E data, in order to create targeted patient cohorts, simulate clinical trials in silico, and rent or license the underlying data to test hypotheses. Through Lens, users can also collaborate to analyze data with Tempus' computational biologists and data scientists. Users can analyze data through a combination of open source and purpose-built Tempus visual analysis tools or a cloud-based data science environment. They can also apply their own proprietary tools to the data, Tempus said.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.